Stock News

Towerview Upped Stake in Alico (ALCO); First American Bank Has Trimmed Position in Edwards Lifesciences Com (EW) by $330,959

Alico, Inc. (NASDAQ:ALCO) Logo

First American Bank decreased its stake in Edwards Lifesciences Corp Com (EW) by 3.85% based on its latest 2018Q1 regulatory filing with the SEC. First American Bank sold 2,381 shares as the company’s stock declined 0.56% with the market. The institutional investor held 59,481 shares of the industrial specialties company at the end of 2018Q1, valued at $8.30 million, down from 61,862 at the end of the previous reported quarter. First American Bank who had been investing in Edwards Lifesciences Corp Com for a number of months, seems to be less bullish one the $32.02 billion market cap company. The stock increased 2.30% or $3.41 during the last trading session, reaching $151.93. About 1.35 million shares traded. Edwards Lifesciences Corporation (NYSE:EW) has risen 19.08% since June 13, 2017 and is uptrending. It has outperformed by 6.51% the S&P500. Some Historical EW News: 30/04/2018 – Edwards Granted CE Mark For First Transcatheter Tricuspid Therapy; 24/04/2018 – EDWARDS LIFESCIENCES – QTRLY TRANSCATHETER HEART VALVE THERAPY SALES OF $551.6 MLN, UP 2.3 PCT; 24/04/2018 – After-hours buzz: TXN, WYNN, EW & more; 24/04/2018 – Edwards Lifesciences 1Q Adj EPS $1.22; 28/03/2018 – Boston Scientific Prevails In U.K. Edwards Lifesciences Litigation; 16/04/2018 – BSX PREVAILS IN PATENT DISPUTE WITH EDWARDS LIFESCIENCES; 15/03/2018 – ClinicalTrial US: Safety and Effectiveness of Edwards Lifesciences SAPIEN 3 Transcatheter Heart Valve (THV) in the Chinese; 26/04/2018 – V-WAVE LTD – CO’S EXISTING INVESTORS, JOHNSON & JOHNSON INNOVATION (JJDC INC.) ,EDWARDS LIFESCIENCES ALSO PARTICIPATED IN FUNDING ROUND; 22/05/2018 – Real-World Evidence Confirms Clinical Trial Outcomes For Patients Treated With Edwards SAPIEN 3 Valve; 16/04/2018 – Boston Scientific Prevails In European Patent Dispute With Edwards Lifesciences

Towerview Llc increased its stake in Alico Inc (ALCO) by 34.04% based on its latest 2018Q1 regulatory filing with the SEC. Towerview Llc bought 18,030 shares as the company’s stock rose 15.01% while stock markets declined. The institutional investor held 71,000 shares of the consumer non-durables company at the end of 2018Q1, valued at $1.93M, up from 52,970 at the end of the previous reported quarter. Towerview Llc who had been investing in Alico Inc for a number of months, seems to be bullish on the $251.34M market cap company. The stock increased 0.83% or $0.25 during the last trading session, reaching $30.55. About 2,954 shares traded. Alico, Inc. (NASDAQ:ALCO) has risen 2.68% since June 13, 2017 and is uptrending. It has underperformed by 9.89% the S&P500. Some Historical ALCO News: 07/05/2018 – ALICO INC – QTRLY ADJ SHR $0.25; 07/05/2018 – ALICO INC – QTRLY TOTAL OPERATING REVENUES $35.6 MLN VS $56.2 MLN; 21/04/2018 DJ Alico Inc, Inst Holders, 1Q 2018 (ALCO); 07/05/2018 – ALICO INC – QTRLY SHR LOSS $0.67; 07/05/2018 – Alico 2Q Rev $35.6M; 07/05/2018 – Alico 2Q Loss/Shr 67c

First American Bank, which manages about $1.32 billion US Long portfolio, upped its stake in Oppenheimer Developing Markets (ODVYX) by 21,594 shares to 371,461 shares, valued at $16.43 million in 2018Q1, according to the filing. It also increased its holding in Wisconsin Elec Pwr Co Note (Prn) by 375,000 shares in the quarter, for a total of 1.15 million shares, and has risen its stake in Exxon Mobil Corp Com (NYSE:XOM).

Analysts await Edwards Lifesciences Corporation (NYSE:EW) to report earnings on July, 25. They expect $1.12 earnings per share, up 3.70% or $0.04 from last year’s $1.08 per share. EW’s profit will be $236.08M for 33.91 P/E if the $1.12 EPS becomes a reality. After $1.22 actual earnings per share reported by Edwards Lifesciences Corporation for the previous quarter, Wall Street now forecasts -8.20% negative EPS growth.

Another recent and important Edwards Lifesciences Corporation (NYSE:EW) news was published by Ocbj.com which published an article titled: “Midday Stock Roundup” on June 13, 2018.

Among 29 analysts covering Edwards Lifesciences Corp (NYSE:EW), 22 have Buy rating, 1 Sell and 6 Hold. Therefore 76% are positive. Edwards Lifesciences Corp had 113 analyst reports since July 30, 2015 according to SRatingsIntel. JP Morgan downgraded the shares of EW in report on Tuesday, January 2 to “Neutral” rating. On Thursday, July 27 the stock rating was upgraded by Bank of America to “Buy”. Canaccord Genuity maintained Edwards Lifesciences Corporation (NYSE:EW) on Sunday, October 8 with “Buy” rating. BMO Capital Markets maintained the shares of EW in report on Wednesday, October 11 with “Buy” rating. As per Tuesday, September 5, the company rating was maintained by Jefferies. Jefferies maintained the shares of EW in report on Friday, May 26 with “Buy” rating. RBC Capital Markets maintained it with “Buy” rating and $140.0 target in Friday, February 2 report. The rating was maintained by Morgan Stanley with “Overweight” on Friday, February 2. Barclays Capital upgraded it to “Buy” rating and $135.0 target in Thursday, January 4 report. The firm has “Equal-Weight” rating given on Thursday, July 27 by Barclays Capital.

Alico, Inc. (NASDAQ:ALCO) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *